Drug Overview

Buparlisib is an experimental cancer medicine currently being studied in clinical trials. It belongs to a modern group of medicines called Targeted Therapies or “Smart Drugs.” Unlike traditional chemotherapy that attacks all fast-growing cells in the body, targeted therapies are designed to find and block specific signals that cancer cells need to grow, multiply, and survive.

Generic Name: Buparlisib (also known in research as BKM120 or AN2025)
US Brand Names: None (Currently an investigational drug)
Drug Class: Pan-PI3K Inhibitor (Targeted Therapy)
Route of Administration: Oral (taken by mouth as a capsule or tablet)
FDA Approval Status: Investigational (Not yet FDA approved for commercial use)

What Is It and How Does It Work? (Mechanism of Action)

Buparlisib is a Targeted Therapy designed to shut down a major communication line inside cancer cells. To stay alive and grow, cancer cells rely on internal signals. One of the most common and powerful signaling pathways used by tumors is called the PI3K/AKT/mTOR pathway.

At the molecular level, buparlisib works by attaching directly to the PI3K (phosphoinositide 3-kinase) enzyme. It specifically blocks all “class I” versions of this enzyme. By plugging into this enzyme, buparlisib acts like a roadblock. It stops the enzyme from turning on other proteins down the line. Because the cancer cell no longer receives the survival and growth signals it needs, it stops dividing and is forced into a natural process of cell death called apoptosis. Additionally, buparlisib has the unique ability to easily cross the blood-brain barrier, allowing it to target cancer cells that may have spread to the brain.

FDA Approved Clinical Indications

Because buparlisib is an investigational medicine, it does not currently have any official FDA-approved uses for the general public. It is only given to patients who volunteer for approved clinical research trials.

Oncological Uses (Investigational)

Treatment of recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Treatment of advanced Breast Cancer (specifically hormone receptor-positive, HER2-negative types).
Treatment of advanced solid tumors that have stopped responding to standard therapies.

Non-Oncological Uses

There are no investigational or approved non-oncological uses for this drug. It is being studied strictly for the treatment of cancer.

Dosage and Administration Protocols

Because buparlisib is still in the testing phase, there is no single commercial prescription dose. The dosages below reflect the standard protocols used during its clinical trials.

Patient Group	Investigational Dose	Frequency	Administration Notes
Adults in Clinical Trials	100 mg	Once daily	Taken by mouth continuously. Often given alongside chemotherapy like paclitaxel.
Patients with Mild to Moderate Hepatic (Liver) Insufficiency	100 mg	Once daily	Mild to moderate liver issues may not require a dose change, but patients are monitored very closely.
Patients with Severe Hepatic Insufficiency	Reduced Dose or Withheld	Varies	The drug is heavily processed by the liver. Severe liver issues require a lower dose (e.g., 50 mg) or pausing the drug entirely.
Patients with Renal (Kidney) Insufficiency	100 mg	Once daily	The kidneys do not do the main work of clearing this drug, so standard doses are typically used unless kidney disease is very severe.

Clinical Efficacy and Research Results

Recent clinical trials (analyzed between 2020 and 2025) have focused heavily on testing buparlisib in patients who have run out of standard treatment options.

Head and Neck Cancer (HNSCC): Buparlisib showed early promise in Phase 2 trials, where patients taking buparlisib combined with chemotherapy lived an average of 10.4 months, compared to 6.5 months for those on chemotherapy alone. However, highly anticipated Phase 3 “BURAN” trial results released in late 2025 revealed that for patients who had already been treated with modern immunotherapy, adding buparlisib to chemotherapy did not significantly improve overall survival compared to chemotherapy alone.
Breast Cancer: In major studies (known as the BELLE trials), buparlisib was able to slightly improve progression-free survival (the amount of time before the tumor starts growing again). Despite this, the drug is not widely used for breast cancer because its side effects were hard for many patients to tolerate compared to newer, more highly specific targeted therapies.

Safety Profile and Side Effects

Buparlisib changes how cells process energy and signals, which can lead to significant side effects. Because it is an investigational drug, it does not have a formal FDA “Black Box Warning,” but researchers strictly monitor for dangerous mental health and liver reactions.

Common Side Effects (>10%)

Hyperglycemia: High blood sugar levels.
Psychiatric Changes: Anxiety, depression, and rapid mood swings. This occurs because the drug easily enters the brain.
Transaminitis: Elevated liver enzymes (ALT and AST) found on blood tests, indicating liver stress.
Gastrointestinal Upset: Nausea, vomiting, and diarrhea.
Fatigue: Feeling unusually tired or lacking energy.
Skin Rash

Serious Adverse Events

Severe Hepatotoxicity: Serious liver damage or severe liver inflammation.
Severe Depression and Suicidality: Major mental health changes requiring immediate psychiatric intervention.
Pneumonitis: Swelling and inflammation in the lungs that can cause severe breathing problems.

Management Strategies

For High Blood Sugar: Doctors will check blood sugar frequently. Some patients may need to temporarily start diabetes medication to keep their sugar levels safe.
For Mood Changes: Patients are closely monitored. If feelings of deep sadness or anxiety begin, the research doctor will likely lower the dose or stop the drug immediately.
For Liver Stress: Routine blood tests are mandatory. If liver enzymes spike to dangerous levels, the drug is paused to allow the liver to heal.

Connection to Stem Cell and Regenerative Medicine

Buparlisib plays an important role in the research of “Cancer Stem Cells.” These are deeply hidden, stubborn “seed” cells that cause cancer to return even after aggressive chemotherapy. Cancer stem cells rely heavily on the PI3K signaling pathway to survive, hide from the immune system, and regenerate. By using a Targeted Therapy like buparlisib to block this pathway, researchers are studying how to eradicate these stem cells completely. If the stem cells are destroyed, the tumor loses its ability to regenerate, offering hope for longer, more permanent remissions.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Before joining a clinical trial for buparlisib, patients will undergo several important health checks:

Fasting Blood Glucose Test: To check baseline blood sugar and screen for diabetes.
Comprehensive Liver Function Tests (LFTs): To ensure the liver is healthy enough to process the medication.
Psychological Evaluation: A screening to check for any history of severe anxiety, depression, or mood disorders.

Precautions During Treatment

Pay very close attention to your mood. Ask a close family member or friend to help monitor your behavior for any sudden sadness or anxiety.
If your doctor asks you to, monitor your blood sugar at home using a standard finger-prick monitor.
Watch for signs of lung inflammation, such as a new, dry cough or feeling out of breath when doing simple tasks.

“Do’s and Don’ts” list

DO tell your clinical trial team about every single medication, vitamin, or supplement you take, as buparlisib interacts with many different drugs.
DO keep all scheduled appointments for your safety blood tests.
DON’T eat grapefruit or drink grapefruit juice. Grapefruit blocks the liver enzymes that clear this medicine, which can cause toxic amounts of the drug to build up in your body.
DON’T stop taking the medicine or change your dose on your own. Always talk to your research doctor first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Buparlisib is an investigational product and is not approved by the FDA for the treatment, cure, or prevention of any disease. Treatment protocols, dosages, and side effects vary by individual and by specific clinical trial guidelines. Patients should always consult with their primary oncologist or a qualified healthcare professional regarding diagnosis, clinical trial options, and the management of medical conditions. Do not disregard professional medical advice or delay in seeking it because of something you have read in this material.